Novel Enteric Budesonide Reduces Proteinuria in IgAN
Overall, patients receiving TRF-budesonide saw a 24.4% reduction in their average urine protein creatinine ratio over 9 months.
A novel targeted-release formulation of the corticosteroid budesonide (TRF-budesonide) could become the first tailored treatment for immunoglobulin A nephropathy (IgAN).
1. FellstrÖm BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 2017;389:2117–27. doi:10.1016/S0140-6736(17)30550-0